Holmes E C, Golub S H
J Thorac Cardiovasc Surg. 1976 Feb;71(2):161-8.
Ninety-three patients with lung cancer were evaluated by delayed cutaneous hypersensitivity testing. Twenty-eight of these patients were evaluated by in vitro lymphocyte function. Thirty-three patients were evaluated prior to surgery and defects in the immune response were closely associated with unresectable disease. In vitro and in vivo studies indicate an antigen recognition defect in the cellular immune mechanisms of these patients. Preliminary studies suggest that the immunopotentiating agent Levamisole may be able to augment this defective cellular immunity in patients with lung cancer.
93例肺癌患者接受了迟发性皮肤超敏反应测试评估。其中28例患者接受了体外淋巴细胞功能评估。33例患者在手术前接受了评估，免疫反应缺陷与不可切除疾病密切相关。体外和体内研究表明这些患者的细胞免疫机制存在抗原识别缺陷。初步研究表明，免疫增强剂左旋咪唑可能能够增强肺癌患者这种有缺陷的细胞免疫。
